文献速递前列腺癌

接受恩扎卢胺或阿比特龙治疗的未经化疗的转移性去势抵抗性前列腺癌男性中不同种族的生存差异

Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-11-03

该研究基于美国退伍军人健康管理局(VHA)数据库,纳入2014年4月至2017年3月期间接受恩扎卢胺或阿比特龙治疗的未经化疗的转移性去势抵抗性前列腺癌(mCRPC)患者2910例(黑人787例,白人2123例),评估种族与总生存(OS)的关系。中位随访黑人19.0个月、白人18.7个月。黑人较白人OS更好,未校正和多变量模型的HR(95%CI)分别为0.89(0.790-0.996;P=0.044)和0.67(0.592-0.758;P<0.0001)。

要点

  • 在VHA数据库中,接受新型内分泌治疗的未经化疗mCRPC黑人患者较白人患者总生存更好。
  • 未校正模型HR 0.89(95%CI 0.790-0.996;P=0.044),多变量模型HR 0.67(95%CI 0.592-0.758;P<0.0001)。
  • 无论后续是否接受治疗,黑人较白人患者均观察到统计学显著更长的OS。

核心结论

  • 在VHA中,接受新型内分泌治疗的未经化疗mCRPC黑人患者可能较接受相似治疗的白人患者有更好的结局。

研究设计与样本

  • 基于VHA数据库的索赔数据分析,通过诊断代码、手术/药物去势证据及2014年4月至2017年3月去势后恩扎卢胺或阿比特龙处方识别年龄≥18岁的mCRPC患者。
  • 共纳入2910例患者(黑人787例,平均71.7岁;白人2123例,平均74.0岁),黑人中位随访19.0个月,白人18.7个月。
  • 采用Cox模型评估种族与OS的关联,在全体人群及根据新型内分泌治疗后是否接受后续治疗划分的亚组中进行未校正和多变量分析。

主要发现

  • 黑人较白人OS更好:未校正模型HR 0.89(95%CI 0.790-0.996;P=0.044),多变量模型HR 0.67(95%CI 0.592-0.758;P<0.0001)。
  • 无论后续治疗类型如何(包括无后续治疗),黑人较白人患者均观察到统计学显著更长的OS。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than white men when treated with certain agents in clinical trials. We analyzed claims data from the Veterans Health Administration (VHA) database to evaluate OS in black and white men treated with enzalutamide or abiraterone (novel hormonal therapy [NHT]) for chemotherapy-naïve mCRPC. METHODS: Patients with mCRPC aged ≥18 years were identified in the VHA database by diagnosis codes, evidence of surgical/medical castration, and a prescription claim for enzalutamide or abiraterone after castration from April 2014-March 2017. Cox models assessed associations between race and OS. Unadjusted and multivariable analyses were performed on the entire population and subsets based on the type of therapy received (if any) after NHT. RESULTS: In total, 2910 patients were identified (787 black, mean 71.7 years; 2123 white, mean 74.0 years). Median follow-up was 19.0 and 18.7 months in blacks and whites, respectively. Black men had better survival versus white men: hazard ratios (95% CIs) were 0.89 (0.790-0.996; P = 0.044) and 0.67 (0.592-0.758; P < 0.0001) in the unadjusted and multivariable models, respectively. Statistically significantly longer OS was seen in black versus white men regardless of subsequent treatment, including no subsequent treatment. CONCLUSIONS: In the VHA, black men with chemotherapy-naïve mCRPC initiating NHT may have better outcomes than similarly treated white men.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. George DJ, Ramaswamy K, Huang A, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 34732856. doi:10.1038/s41391-021-00463-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。